The PPARα–leukotriene B4 pathway to inflammation control
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Inflammation is a local immune response to 'foreign' molecules, infection and injury. Leukotriene B4, a potent chemotactic agent that initiates, coordinates, sustains and amplifies the inflammatory response, is shown to be an activating ligand for the transcription factor PPARalpha. Because PPARalpha regulates the oxidative degradation of fatty acids and their derivatives, like this lipid mediator, a feedback mechanism is proposed that controls the duration of an inflammatory response and the clearance of leukotriene B4 in the liver. Thus PPARalpha offers a new route to the development of anti- or pro-inflammatory reagents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FFAs act as PPAR agonists facilitating translocation to the nucleus and dimerization to RXR [77,78].”
From Lipoprotein Lipase Regulates Microglial Lipid Droplet Accumulation (2021) · cites this paper as [77]
In the citing paper
“PPAR-α is involved in the regulation of pro-inflammatory genes, mainly by limiting cytokine expression.[109]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [109]
Citations
Cites
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects
Samuelsson, B., Dahlén, S.-E., Lindgren, J. Å., Rouzer, C. A., & Serhan, C. N. (1987) · Science · doi:10.1126/science.2820055 · Cited by 2,233
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Self-citationKliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., & Evans, R. M. (1992) · Nature · doi:10.1038/358771a0 · Cited by 1,741
Lee, S. S.-T., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., & Gonzalez, F. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3012 · Cited by 1,655
Self-citationKliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., & Evans, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7355 · Cited by 1,400
Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., & Wahli, W. (1992) · Cell · doi:10.1016/0092-8674(92)90031-7 · Cited by 1,376
Self-citation
Research works printed but not linked: 6
- Ford-Hutchinson, A. W. Crit. Rev. Immunol. 10, 1–11 (1990).
- Desvergne, B. & Wahli, W. in Inducible Transcription Vol. 1 (ed. Bæuerle, P.) 142–176 (Birkhäuser, Boston, 1995).
- Greene, M. E. et al. Gene Expr. 4, 281–299 (1995).
- Schmidt, A. et al. Mol. Endocrinol. 6, 1634–1641 (1992).
- Yu, K. et al. J. Biol. Chem. 270, 23975–23983 (1995). · DOI · Paper page
- Peters, J. M. et al. Mol. Pharmacol. 50, 67–94 (1996).
Cited by
Items 101–200 of 1,001
Tsubouchi, Y., Sano, H., Kawahito, Y., Mukai, S., Yamada, R., Kohno, M., Inoue, K.-I., Hla, T., & Kondo, M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2436 · Cited by 315
PPARs: transcriptional effectors of fatty acids and their derivatives
Hihi, A. K., Michalik, L., & Wahli, W. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8467-x · Cited by 311
Self-citationRegulation of Ketone Body Metabolism and the Role of PPARα
Grabacka, M., Pierzchalska, M., Dean, M., & Reiss, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122093 · Cited by 305
Role of redox-regulated transcription factors in inflammation, aging and age-related diseases
Lavrovsky, Y. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00118-2 · Cited by 304
Regulation of Macrophage Functions by PPAR-α, PPAR-γ, and LXRs in Mice and Men
Rigamonti, E., Chinetti-Gbaguidi, G., & Staels, B. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.158998 · Cited by 293
Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation.
Thunnissen, M. M. G. M., Nordlund, P., & Haeggström, J. Z. (2001) · Nature Structural Biology · doi:10.1038/84117 · Cited by 300
Vu-Dac, N., Chopin-Delannoy, S., Gervois, P., Bonnelye, E., Martin, G., Fruchart, J.-C., Laudet, V., & Staels, B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25713 · Cited by 297
Gonzalez, F. J., Peters, J. M., & Cattley, R. C. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.22.1702 · Cited by 290
Self-citationClaudel, T., Leibowitz, M. D., Fiévet, C., Tailleux, A., Wagner, B., Repa, J. J., Torpier, G., Lobaccaro, J.-M., Paterniti, J. R., Mangelsdorf, D. J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041609298 · Cited by 292
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
Guan, Y., & Breyer, M. D. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00766.x · Cited by 295
International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors
Brink, C., Dahlén, S.-E., Drazen, J., Evans, J. F., Hay, D. W. P., Nicosia, S., Serhan, C. N., Shimizu, T., & Yokomizo, T. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.8 · Cited by 286
“…Goetzl and Picket, 1980; Serhan et al., 1982 Cytokine secretion Luscinskas et al., 1990; Rola-Pleszczynski et al., 1993 Nuclear transcription (PPAR ) Devchand et al., 1996 IgE synthesis Odlander et al., 1988; Yamaoki et al., 1994 Cysteinyl-leukotrienes (LTC4, LTD4, LTE4) Bronchospasm Drazen et…”
BackgroundCell biology and molecular mechanisms of injury in ischemic acute renal failure
Sheridan, A. M., & Bonventre, J. V. (2000) · Current Opinion in Nephrology and Hypertension · doi:10.1097/00041552-200007000-00015 · Cited by 288
Fiorucci, S., Meli, R., Bucci, M., & Cirino, G. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00747-x · Cited by 285
Reginato, M. J., Krakow, S. L., Bailey, S. T., & Lazar, M. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.4.1855 · Cited by 277
Inoue, I., Goto, S.-I., Matsunaga, T., Nakajima, T., Awata, T., Hokari, S., Komoda, T., & Katayama, S. (2001) · Metabolism · doi:10.1053/meta.2001.19415 · Cited by 283
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
“For example, inflammatory mediators and PPARα ligand, leukotriene B4 can exert a negative feedback mechanism via PPARα activation to limit its activity and to resolve an inflammatory response [28].”
BackgroundAngiotensin II is associated with activation of NF-κB-mediated genes and downregulation of PPARs
Tham, D. M., Martin-McNulty, B., Wang, Y.-X., Wilson, D. W., Vergona, R., Sullivan, M. E., Dole, W., & Rutledge, J. C. (2002) · Physiological Genomics · doi:10.1152/physiolgenomics.00062.2002 · Cited by 277
DeWitt, J. C., Shnyra, A., Badr, M. Z., Loveless, S. E., Hoban, D., Frame, S. R., Cunard, R., Anderson, S. E., Meade, B. J., Peden-Adams, M. M., et al. (2009) · Critical Reviews in Toxicology · doi:10.1080/10408440802209804 · Cited by 266
“It has also been suggested that, given the promiscuous nature of PPARα, the ligands could regulate their own inactivation or clearance through activation of the receptor and, thus, influence the extent of the inflammatory response (Devchand et al., 1996).”
BackgroundPanigrahy, D., Kaipainen, A., Huang, S., Butterfield, C. E., Barnés, C. M., Fannon, M., Laforme, A. M., Chaponis, D. M., Folkman, J., & Kieran, M. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711281105 · Cited by 269
Qiu, Y.-Y., Zhang, J., Zeng, F.-Y., & Zhu, Y. Z. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106786 · Cited by 271
van Raalte, D. H., Li, M., Pritchard, P. H., & Wasan, K. M. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000041444.06122.8d · Cited by 269
“The first indication that PPAR- modulates vascular inflammation came from a study in PPAR- (−/−) mice, which showed a prolonged inflammatory response (29).”
BackgroundRegulators of endothelial and epithelial barrier integrity and function in acute lung injury
Lucas, R., Verin, A. D., Black, S. M., & Catravas, J. D. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.01.014 · Cited by 263
Alestas, T., Ganceviciene, R., Fimmel, S., Müller-Decker, K., & Zouboulis, C. C. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0715-8 · Cited by 269
“In addition, our in vitro finding of LTB4 inducing down-regulation of the abundant PPARα mRNA levels in sebocytes makes a reduction of lipid oxidation and catabolism, including that of LTB4, probable [18, 48].”
BackgroundTanaka, T., Kohno, H., Yoshitani, S., Takashima, S., Okumura, A., Murakami, A., & Hosokawa, M. (2001) · PubMed · Cited by 290
Ren, B., Thelen, A. P., Peters, J. M., Gonzalez, F. J., & Jump, D. B. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.43.26827 · Cited by 264
Self-citationLigand Selectivity of the Peroxisome Proliferator-Activated Receptor α
Lin, Q., Ruuska, S. E., Shaw, N. S., Dong, D., & Noy, N. (1999) · Biochemistry · doi:10.1021/bi9816094 · Cited by 263
PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253
Ward, J. M., Peters, J. M., Perella, C. M., & Gonzalez, F. J. (1998) · Toxicologic Pathology · doi:10.1177/019262339802600208 · Cited by 249
Self-citationThe search for the palmitoylethanolamide receptor
LoVerme, J., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.012 · Cited by 248
“Mice lacking the gene encoding for PPAR-a display prolonged inflammatory responses (Devchand et al., 1996) and synthetic agonists of this receptor cause profound anti-inflammatory effects (Chinetti et al., 2000; LoVerme et al., 2005; Sheu et al., 2002).”
BackgroundAntioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders
Darlington, L. G., & Stone, T. W. (2001) · British Journal of Nutrition · doi:10.1079/bjn2000239 · Cited by 245
“LTB 4 has been considered to be a pivotal agent in the development of inflammatory responses (Devchand et al. 1996).”
The Regulation of Chondrocyte Function by Proinflammatory Mediators: Prostaglandins and Nitric Oxide
Goldring, M. B., & Berenbaum, F. (2004) · Clinical Orthopaedics & Related Research · doi:10.1097/01.blo.0000144484.69656.e4 · Cited by 245
Woerly, G., Honda, K., Loyens, M., Papin, J.-P., Auwerx, J., Staels, B., Capron, M., & Dombrowicz, D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021384 · Cited by 244
“LTB4, a natural PPAR-� ligand ( 5 ), is abundantly produced, among other cell types, by mast cells in inflammatory reactions such as asthma (46) and is highly chemotactic for eosinophils that express a specific membrane LTB4 receptor: BLTR (35).”
BackgroundInfluentialDo Peroxisome Proliferating Compounds Pose a Hepatocarcinogenic Hazard to Humans?
Cattley, R. C., DeLuca, J., Elcombe, C., Fenner-Crisp, P., Lake, B. G., Marsman, D. S., Pastoor, T. A., Popp, J. A., Robinson, D. E., Schwetz, B., et al. (1998) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1997.1163 · Cited by 244
Self-citationInvolvement of PPAR nuclear receptors in tissue injury and wound repair
Michalik, L. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27958 · Cited by 239
Peripheral gating of pain signals by endogenous lipid mediators
Piomelli, D., & Sasso, O. (2014) · Nature Neuroscience · doi:10.1038/nn.3612 · Cited by 246
Regulation of Cytokine Expression by Ligands of Peroxisome Proliferator Activated Receptors
Cunard, R., Ricote, M., DiCampli, D., Archer, D. C., Kahn, D. A., Glass, C. K., & Kelly, C. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.6.2795 · Cited by 238
“Most recently, PPARs have been shown to mediate antiinflammatory activities (3, 9, 10), and the majority of these studies have focused on effects in monocyte/macrophages and endothelial cells.”
BackgroundYoung, P. W., Buckle, D. R., Cantello, B. C. C., Chapman, H., Clapham, J. C., Coyle, P. J., Haigh, D., Hindley, R. M., Holder, J. C., Kallender, H., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37268-4 · Cited by 101
“Moreover, direct binding of [3H]leukotriene B4 to E. coliexpressed PPARa LBD-GST fusion protein has recently been reported, suggesting that the LBD, of this PPAR isoform at least, folds correctly after cell lysis (Devchand et al., 1996).”
Colville-Nash, P. R., Qureshi, S. S., Willis, D., & Willoughby, D. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.978 · Cited by 241
A Regulatory Role for RIP140 in Nuclear Receptor Activation
Treuter, E. (1998) · Molecular Endocrinology · doi:10.1210/me.12.6.864 · Cited by 230
Stoichiometric and steric principles governing repression by nuclear hormone receptors.
Zamir, I., Zhang, J., & Lazar, M. A. (1997) · Genes & Development · doi:10.1101/gad.11.7.835 · Cited by 232
Serhan, C. N. (1996) · Nature · doi:10.1038/384023a0 · Cited by 234
Torra, I. P., Gervois, P., & Staels, B. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199904000-00009 · Cited by 231
Shu, H., Wong, B., Zhou, G., Li, Y., Berger, J., Woods, J. W., Wright, S. D., & Cai, T.-Q. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1968 · Cited by 229
Leukotriene B4: Metabolism and Signal Transduction
Yokomizo, T., Izumi, T., & Shimizu, T. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.2168 · Cited by 231
Fowler, A. J., Sheu, M. Y., Schmuth, M., Kao, J., Fluhr, J. W., Rhein, L., Collins, J. L., Willson, T. M., Mangelsdorf, D. J., Elias, P. M., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12033.x · Cited by 229
“In addition, ligands of RAR, vitamin D receptor, and PPAR display selected types of anti-inflammatory activity”
BackgroundModulation of immune function by dietary fatty acids
Miles, E. A., & Calder, P. C. (1998) · Proceedings of the Nutrition Society · doi:10.1079/pns19980042 · Cited by 227
“…situation will be more complex, because 4-series LT enhance TNF, IL-1 and IL-6 production (Kunkel et al. 1982; Rola-Pleszczynski & Lemaire, 1985; Dubois et al. 1989; Gagnon et al. 1989; Schade et al. 1989; Poubelle et al. 1991) and fish-oil feeding will decrease 4-series LT production (for…”
INTRACELLULAR LIPID-BINDING PROTEINS AND THEIR GENES
Bernlohr, D. A., Simpson, M. A., Hertzel, A. V., & Banaszak, L. J. (1997) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.17.1.277 · Cited by 227
Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans
Guan, Y., Zhang, Y., Davis, L., & Breyer, M. D. (1997) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1997.273.6.f1013 · Cited by 226
A Paradigm for Gene Regulation: Inflammation, NF-κB and PPAR
Vanden Berghe, W., Vermeulen, L., Delerive, P., De Bosscher, K., Staels, B., & Haegeman, G. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-9072-3_22 · Cited by 222
Lazennec, G. (2000) · Molecular Endocrinology · doi:10.1210/me.14.12.1962 · Cited by 220
Self-citationEhrenborg, E., & Krook, A. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001560 · Cited by 213
“…acid and leukotriene B4, whereas 9-hydroxy-10,12-octadecadienoic acid, 13-hydroxy-9,11-octadecadienoic acid, and 15 -deoxy-12,14-prostaglandin J2 activate PPAR (Forman et al., 1995; Kliewer et al., 1995; Devchand et al., 1996; Kliewer et al., 1997; Nagy et al., 1998; Lin et al., 1999).”
PPARα in atherosclerosis and inflammation
ZANDBERGEN, F., & PLUTZKY, J. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.021 · Cited by 214
Liang, Y.-C., Tsai, S.-H., Tsai, D.-C., Lin-Shiau, S.-Y., & Lin, J.-K. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02393-6 · Cited by 217
Peroxisome proliferator-activated receptor α protects against alcohol-induced liver damage
Nakajima, T., Kamijo, Y., Tanaka, N., Sugiyama, E., Tanaka, E., Kiyosawa, K., Fukushima, Y., Peters, J. M., Gonzalez, F. J., & Aoyama, T. (2004) · Hepatology · doi:10.1002/hep.1840400428 · Cited by 158
Self-citationNarravula, S., & Colgan, S. P. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7543 · Cited by 218
Dharancy, S., Malapel, M., Perlemuter, G., Roskams, T., Cheng, Y., Dubuquoy, L., Podevin, P., Conti, F., Canva, V., Philippe, D., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.016 · Cited by 207
Be Fit or Be Sick: Peroxisome Proliferator-Activated Receptors Are Down the Road
Desvergne, B., Michalik, L., & Wahli, W. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0088 · Cited by 222
Self-citationAbbott, B. D. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2008.10.001 · Cited by 218
PPARs and lipid ligands in inflammation and metabolism
Harmon, G. S., Lam, M. T., & Glass, C. K. (2011) · Chemical Reviews · doi:10.1021/cr2001355 · Cited by 216
Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease
Sanyal, A. J. (2005) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0084 · Cited by 216
Target Genes of Peroxisome Proliferator-activated Receptor γ in Colorectal Cancer Cells
Gupta, R. A., Brockman, J. A., Sarraf, P., Willson, T. M., & DuBois, R. N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103779200 · Cited by 215
Cuzzocrea, S., Pisano, B., Dugo, L., Ianaro, A., Maffia, P., Patel, N. S. A., Di Paola, R., Ialenti, A., Genovese, T., Chatterjee, P. K., et al. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.10.056 · Cited by 214
RetractedCarcinogenesis: Failure of resolution of inflammation?
Fishbein, A., Hammock, B. D., Serhan, C. N., & Panigrahy, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107670 · Cited by 205
Gervois, P., Kleemann, R., Pilon, A., Percevault, F., Koenig, W., Staels, B., & Kooistra, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400346200 · Cited by 212
Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis
Neve, B. P., Fruchart, J.-C., & Staels, B. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00430-5 · Cited by 211
PPARs and the Cardiovascular System
Hamblin, M., Chang, L., Fan, Y., Zhang, J., & Chen, Y. E. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2280 · Cited by 207
Role of Leukotriene B4Receptors in the Development of Atherosclerosis: Potential Mechanisms
Subbarao, K., Jala, V. R., Mathis, S., Suttles, J., Zacharias, W., Ahamed, J., Ali, H., Tseng, M. T., & Haribabu, B. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000110503.16605.15 · Cited by 208
Oxidized phospholipids activate PPARα in a phospholipase A2‐dependent manner
Delerive, P., Furman, C., Teissier, E., Fruchart, J.-C., Duriez, P., & Staels, B. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01364-8 · Cited by 199
Role of transcription factors in mediating post-ischemic cerebral inflammation and brain damage
YI, J., PARK, S., KAPADIA, R., & VEMUGANTI, R. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.04.019 · Cited by 206
The peroxisome: still a mysterious organelle
Schrader, M., & Fahimi, H. D. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0396-9 · Cited by 191
“The anti-inXammatory function of peroxisomes and the regulatory role of PPAR-activators in this process were discovered more than a decade ago (Devchand et al. 1996).”
BackgroundPeroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease
Lovett-Racke, A. E., Hussain, R. Z., Northrop, S., Choy, J., Rocchini, A., Matthes, L., Chavis, J. A., Diab, A., Drew, P. D., & Racke, M. K. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5790 · Cited by 207
Fahmi, H., Di Battista, J. A., Pelletier, J.-P., Mineau, F., Ranger, P., & Martel-Pelletier, J. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200103)44:3<595::aid-anr108>3.0.co;2-8 · Cited by 203
The Role of IL‐1 and IL‐1Ra in Joint Inflammation and Cartilage Degradation
Jacques, C., Gosset, M., Berenbaum, F., & Gabay, C. (2006) · Vitamins & Hormones · doi:10.1016/s0083-6729(06)74016-x · Cited by 196
Inoue, I., Shino, K., Noji, S., Awata, T., & Katayama, S. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8622 · Cited by 199
Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions
Michalik, L., & Wahli, W. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)00030-0 · Cited by 202
Self-citationCowart, L. A., Wei, S., Hsu, M.-H., Johnson, E. F., Krishna, M. U., Falck, J. R., & Capdevila, J. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201575200 · Cited by 195
Immunomodulation by Polyunsaturated Fatty Acids: Mechanisms and Effects
Stulnig, T. M. (2003) · International Archives of Allergy and Immunology · doi:10.1159/000074898 · Cited by 198
“but there is no evidence for involvement of HNF4α in the immune response.Antiinflammatory effects of nuclear receptors have mostly been studied for PPARs and particularly on monocytes/macrophages [”
BackgroundPeroxisome proliferator-activated receptor agonists
Willson, T. M., & Wahli, W. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80015-4 · Cited by 198
Self-citationPeroxisome Proliferator-Activated Receptor α Protects against Obesity-Induced Hepatic Inflammation
Stienstra, R., Mandard, S., Patsouris, D., Maass, C., Kersten, S., & Müller, M. (2007) · Endocrinology · doi:10.1210/en.2007-0014 · Cited by 191
Peters-Golden, M., & Brock, T. G. (2003) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(03)00070-x · Cited by 197
Tang, H., & McLachlan, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1841 · Cited by 183
Lipid Mediators in Inflammation
Bennett, M., & Gilroy, D. W. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0035-2016 · Cited by 172
Current Evidence Linking Polyunsaturated Fatty Acids with Cancer Risk and Progression
Azrad, M., Turgeon, C., & Demark-Wahnefried, W. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00224 · Cited by 189
Tager, A. M., Dufour, J. H., Goodarzi, K., Bercury, S. D., von Andrian, U. H., & Luster, A. D. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.3.439 · Cited by 195
“Whereas BLTR appears to mediate the proinflammatory leukocyte recruitment induced by LTB 4 , PPAR a activation appears to have antiinflammatory effects, as suggested by the observation of prolonged inflammation in PPAR a -deficient mice when challenged with LTB 4 or its precursor, arachidonic acid ( 11 ).”
BackgroundPPARα Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages
Neve, B. P., Corseaux, D., Chinetti, G., Zawadzki, C., Fruchart, J.-C., Duriez, P., Staels, B., & Jude, B. (2001) · Circulation · doi:10.1161/01.cir.103.2.207 · Cited by 191
Localization and regulation of cytosolic phospholipase A2
Hirabayashi, T., & Shimizu, T. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00115-3 · Cited by 188
Leukotriene A4 Hydrolase/Aminopeptidase, the Gatekeeper of Chemotactic Leukotriene B4 Biosynthesis
Haeggström, J. Z. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400027200 · Cited by 188
Immunoregulatory and anti-inflammatory effects of n-3 polyunsaturated fatty acids
Calder, P. C. (1998) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x1998000400002 · Cited by 187
Kuwata, H., Nakatani, Y., Murakami, M., & Kudo, I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.3.1733 · Cited by 187
Iñiguez, M. A., Punzón, C., & Fresno, M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.111 · Cited by 185
Perreault, L., Newsom, S. A., Strauss, A., Kerege, A., Kahn, D. E., Harrison, K. A., Snell-Bergeon, J. K., Nemkov, T., D’Alessandro, A., Jackman, M. R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96805 · Cited by 184
Human skin: an independent peripheral endocrine organ
Zouboulis, C. C. (2000) · Hormone Research in Paediatrics · doi:10.1159/000053265 · Cited by 183
Endogenous Ligands for Nuclear Receptors: Digging Deeper
Schupp, M., & Lazar, M. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.182451 · Cited by 182
Tumor Necrosis Factor α and Interleukin 1β Enhance the Cortisone/Cortisol Shuttle
Escher, G., Galli, I., Vishwanath, B. S., Frey, B. M., & Frey, F. J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.2.189 · Cited by 179
Phosphorylation of PPARs: from molecular characterization to physiological relevance
Diradourian, C., Girard, J., & Pégorier, J.-P. (2005) · Biochimie · doi:10.1016/j.biochi.2004.11.010 · Cited by 178
Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives
Chapman, M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00156-4 · Cited by 180
Ottaviani, M., Alestas, T., Flori, E., Mastrofrancesco, A., Zouboulis, C. C., & Picardo, M. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700434 · Cited by 175
Fatty acids as gatekeepers of immune cell regulation
Yaqoob, P. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.10.002 · Cited by 176
PPARs: Transcription Factors Controlling Lipid and Lipoprotein Metabolism
BOCHER, V., PINEDA‐TORRA, I., FRUCHART, J., & STAELS, B. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04258.x · Cited by 178
p300 Functions as a Coactivator for the Peroxisome Proliferator-activated Receptor α
Dowell, P., Ishmael, J. E., Avram, D., Peterson, V. J., Nevrivy, D. J., & Leid, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.52.33435 · Cited by 176
Metadata
- Authors
- Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W.
- Affiliations
- University of Lausanne (CH)
- National Institutes of Health (US)
- Venue
- Nature
- Published
- 1996-11
- Volume
- 384
- Issue
- 6604
- Pages
- 39-43
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1671834350
- Cited by
- 1,345
- References
- 43
- Citations by year
- 2026: 3 · 2025: 17 · 2024: 14 · 2023: 21 · 2022: 9 · 2021: 38 · 2020: 30 · 2019: 23 · 2018: 21 · 2017: 24 · 2016: 23 · 2015: 22 · 2014: 43 · 2013: 34 · 2012: 49
- FWCI
- 28.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- PPARα, leukotriene B4, inflammation, transcription factor activation, fatty acid oxidation, lipid mediators, chemotaxis, anti-inflammatory agents, liver, feedback regulation
- MeSH terms
- Adaptation, Physiological, Animals, Cells, Cultured, Fatty Acids, Female, Gene Expression Regulation, HeLa Cells, Humans, Inflammation, Leukotriene B4, Ligands, Liver, Male, Oxidation-Reduction, Plasmids, Pyrimidines, Time Factors, Transcription Factors, Transfection, Chloramphenicol O-Acetyltransferase, Arachidonic Acid, Rats, Sprague-Dawley, Receptors, Cytoplasmic and Nuclear, Inflammation Mediators, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.